Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Prostate Cancer

  Free Subscription


Articles published in Urol Int

Retrieve available abstracts of 29 articles:
HTML format



Single Articles


    August 2025
  1. LUO H, Liao G, Liu Y
    Efficacy of Neoadjuvant Hormone Therapy Combined with Radical Prostatectomy in Improving Oncological Outcomes for Patients with cT3 Prostate Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2025 Aug 13:1-37. doi: 10.1159/000547875.
    PubMed     Abstract available


    July 2025
  2. PHILIPPOU C, Gloger S, Ubrig B, Bitterlich N, et al
    Estimating Bone Metastasis Risk in Prostate Cancer: A Three-Parameter Model using BSP, ISUP Grading, and Tumor Progression.
    Urol Int. 2025 Jul 25:1-34. doi: 10.1159/000547556.
    PubMed     Abstract available


    June 2025
  3. PINA-VAZ T, Costa Silva A, Costa G, Goncalves M, et al
    Sexually Transmitted Infections in Prostate Cancer: A Prospective Multicenter Analysis.
    Urol Int. 2025 Jun 21:1-13. doi: 10.1159/000545208.
    PubMed     Abstract available


    May 2025
  4. NIRAZUKA A, Nakayama A, Inoue M, Tsujioka H, et al
    Impact of an Early Prostate-Specific Antigen Response on Biochemical Progression During Upfront Androgen Receptor Signal Inhibitor Therapy for Metastatic Hormone-Sensitive Prostate Cancer.
    Urol Int. 2025 May 22:1-18. doi: 10.1159/000546327.
    PubMed     Abstract available


    April 2025
  5. BORKOWETZ A, Wullich B, Saar M, Schmidt-Hegemann N, et al
    Treatment strategies in oligo-metastatic prostate cancer - a nation-wide survey.
    Urol Int. 2025 Apr 14:1-20. doi: 10.1159/000545630.
    PubMed     Abstract available


    January 2025
  6. FIORELLO N, Zucchi A, Gregori F, Romei G, et al
    Urinary Leakage after Robot-Assisted Radical Prostatectomy: Is Always Predictive of Functional Results?
    Urol Int. 2025;109:68-73.
    PubMed     Abstract available


  7. ELLEISY M, Drager DL, Zettl H, Hakenberg OW, et al
    COVID-19 Pandemic Impact on Uro-Oncological Disease Outcomes at a German Referral Center.
    Urol Int. 2025;109:135-145.
    PubMed     Abstract available


  8. SPACHMANN PJ, Witt D, Breyer J, Denzinger S, et al
    Antibiotic Prophylaxis of Transrectal Biopsy of the Prostate: A Plea for Fosfomycin.
    Urol Int. 2025;109:146-150.
    PubMed     Abstract available


  9. ELLEISY M, Zettl H, Drager DL, Hakenberg OW, et al
    The Impact of Diabetes and Antidiabetics on Uro-Oncological Disease Outcomes: A Single-Center Experience.
    Urol Int. 2025;109:361-371.
    PubMed     Abstract available


    October 2024
  10. JI G, Liu F, Chen Z, Peng J, et al
    Correlation of magnetic resonance imaging and computed tomography with biological factor expression and lymph node metastasis in aggressive prostate cancer.
    Urol Int. 2024 Oct 25:1-8. doi: 10.1159/000541953.
    PubMed     Abstract available


  11. YU J, Zhou K, Wang J, Mao L, et al
    Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration?resistant prostate cancer: a single-center, open-label study.
    Urol Int. 2024 Oct 15:1-13. doi: 10.1159/000541929.
    PubMed     Abstract available


  12. OPPOLZER IA, Schnabel MJ, Hammer S, Zilles H, et al
    Impact of SARS-CoV-2-Pandemic on diagnosis of prostate cancer.
    Urol Int. 2024 Oct 3:1-15. doi: 10.1159/000541753.
    PubMed     Abstract available


    September 2024
  13. BULBUL O, Nak D, Goksel S
    Prediction of lesion-based treatment response after two cycles of Lu-177 PSMA treatment in metastatic castration-resistant prostate cancer using machine learning.
    Urol Int. 2024 Sep 30:1-12. doi: 10.1159/000541628.
    PubMed     Abstract available


    August 2024
  14. OBERNEDER M, Henzler T, Kriegmair M, Vag T, et al
    Prediction of clinically significant prostate cancer using multi parametric MRI, biparametric MRI and clinical parameters.
    Urol Int. 2024 Aug 31. doi: 10.1159/000541152.
    PubMed     Abstract available


    May 2024
  15. GLOGER S, Paulics L, Philippou C, Philippou S, et al
    Perioperative rates of incidental prostate cancer after aquablation and holmium laser enucleation of the prostate (HoLEP).
    Urol Int. 2024 May 27. doi: 10.1159/000539014.
    PubMed     Abstract available


    March 2024
  16. SIMSEK A, Celen S, Duran MB, Kucuker K, et al
    THE DIAGNOSTIC ACCURACY OF A COMBINATION OF PREOPERATIVE 68-Ga PSMA PET/CT AND MULTIPARAMETRIC MRI IN LOCALIZED PROSTATE CANCER.
    Urol Int. 2024 Mar 13. doi: 10.1159/000538061.
    PubMed     Abstract available


  17. HU S, Xiong X, Qiu S, Li J, et al
    Comparing efficacies of different exercises on androgen deprivation therapy adverse effects in prostate cancer patients: a network meta-analysis.
    Urol Int. 2024 Mar 2. doi: 10.1159/000538114.
    PubMed     Abstract available


    January 2024
  18. RIEDEL A, Michael M, Grunberg J, Mehralivand S, et al
    The role of multiparametric MRI (mpMRI) in the prediction of adverse prostate cancer pathology in radical prostatectomy specimen.
    Urol Int. 2024 Jan 19. doi: 10.1159/000536256.
    PubMed     Abstract available


  19. WU S, Feldman AS, Lin SX, Kim MM, et al
    Estimated Prostate Volume by Semiautomatic Segmentation of MRI Is More Accurately Correlated with Radical Prostatectomy Specimen Weight than the Volume Calculated by Ellipsoid Formula.
    Urol Int. 2024;108:35-41.
    PubMed     Abstract available


  20. SIGG S, Arnold W, Grossmann NC, Baumeister P, et al
    Why Do Men Reject Adjuvant Radiotherapy following Radical Prostatectomy? A Systematic Survey.
    Urol Int. 2024;108:211-218.
    PubMed     Abstract available


  21. FARZAT M, Wagenlehner FM
    How Might the Number of Lymph Nodes Removed during RARP Impact the Postoperative Outcomes?
    Urol Int. 2024;108:175-182.
    PubMed     Abstract available


  22. FERRANDINO MN, Espino G, Young M, Bodden E, et al
    Initial Experience with an Absorbable Urologic Scaffold to Mitigate Early Urinary Incontinence following Radical Prostatectomy: A Report of 2 Cases.
    Urol Int. 2024;108:574-577.
    PubMed     Abstract available


    November 2023
  23. CANKAYA S, Caylan AE, Aydin F, Ucar M, et al
    Correlation between prostate cancer positive cores and 68Ga-PSMA distribution in prostate gland.
    Urol Int. 2023 Nov 28. doi: 10.1159/000535466.
    PubMed     Abstract available


  24. CUI Y, Zhao J, Sun Y
    The Value of the Prostate Health Index and Derived Indexes in the Diagnosis of Prostate Cancer with PI-RADS-3 Lesions.
    Urol Int. 2023 Nov 27:1-6. doi: 10.1159/000534597.
    PubMed     Abstract available


  25. SENEL S, Koudonas A, Uzun E, Ceviz K, et al
    The Value of Prostate-Specific Antigen Density in Combination with Lesion Diameter for the Accuracy of Prostate Cancer Prediction in Prostate Imaging-Reporting and Data System 3 Prostate Lesions.
    Urol Int. 2023 Nov 20:1-6. doi: 10.1159/000534805.
    PubMed     Abstract available


  26. SIKIC D, Fiebig C, Wullich B, Wolff I, et al
    Patient Benefits of Radical Prostatectomy in Certified Prostate Cancer Centers: Comparative Results from the Multicenter IMPROVE Study.
    Urol Int. 2023 Nov 6:1-10. doi: 10.1159/000534486.
    PubMed     Abstract available


    January 2023
  27. SHEN C, Zhang DL, Cheng XL, Zhang WC, et al
    Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
    Urol Int. 2023;107:841-847.
    PubMed     Abstract available


  28. SCARCIA M, Moretto S, Zazzara M, Alba S, et al
    Robot-Assisted Extraperitoneal Radical Prostatectomy for Giant Multilocular Prostatic Cystadenoma: A Case Report and Literature Review.
    Urol Int. 2023;107.
    PubMed     Abstract available


  29. STOLZENBACH LF, Fankhauser CD, Mattei A, Wurnschimmel C, et al
    Solitary Fibrous Tumor of the Prostate Treated with Frozen-Section Supported Robot-Assisted Nerve-Sparing Radical Prostatectomy.
    Urol Int. 2023;107.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.